open access

Ahead of print
Research paper
Published online: 2021-06-17
Get Citation

Safety and Tolerability of Sodium Glucose Co-transporter -2 Inhibitors (SGLT2i) During Ramadan Fasting

Elsayed A. Eid, Abdelaziz M. Hussein, Hossam A. Ghazy
DOI: 10.5603/DK.a2021.0048

open access

Ahead of print
Original articles (submitted)
Published online: 2021-06-17

Abstract

Background: Diabetic management during Ramadan fasting is a significant clinical challenge. Sodium glucose co-transporter -2 inhibitors (SGLT2i) are new class of antidiabetic medications known for low frequency of associated hypoglycemia. The present study aimed to evaluate efficacy, safety and tolerability of SGLT2i in diabetic patients practicing Ramadan fasting. Patients and methods: The study included 94 patients. They comprised 51 patients who received metformin and sulfonylureas (SU): glimepiride (1-6 mg/d) or gliclazide MR (60-120mg/d) and 43 patients who received metformin and SGLT2i: empagliflozin (25 mg), dapagliflozin (10 mg) or canagliflozin (300 mg). The study outcome parameters were frequency of hypoglycemia episodes, volume depletion episodes, number of days with early breaking of fasting and missed fasting days. Results: It was found that patients in SGLTi group experiences significantly fewer symptomatic (9.3 % versus 35.3 %, p=0.003) and documented (7.0 % versus 25.5 %, p=0.017) hypoglycemic episodes as compared to the SU group. However, there were no significant differences between the studied groups regarding the frequency of patients with volume depletion episodes (5.9 % versus 16.3 %, p= 0.1). Moreover, there were no significant differences between groups regarding the frequency of patients with early breaking of fasting (11.8 % versus 9.3 %, p=0.7) or missed fasting (3.9 % versus 2.3 %, p=0.66). None of the studied patients discontinued the prescribed medications. Conclusions: SGLT2i combined with metformin for diabetic patients during Ramadan fasting are effective, safe and well-tolerated with the advantage of reduced hypoglycemic events.

Abstract

Background: Diabetic management during Ramadan fasting is a significant clinical challenge. Sodium glucose co-transporter -2 inhibitors (SGLT2i) are new class of antidiabetic medications known for low frequency of associated hypoglycemia. The present study aimed to evaluate efficacy, safety and tolerability of SGLT2i in diabetic patients practicing Ramadan fasting. Patients and methods: The study included 94 patients. They comprised 51 patients who received metformin and sulfonylureas (SU): glimepiride (1-6 mg/d) or gliclazide MR (60-120mg/d) and 43 patients who received metformin and SGLT2i: empagliflozin (25 mg), dapagliflozin (10 mg) or canagliflozin (300 mg). The study outcome parameters were frequency of hypoglycemia episodes, volume depletion episodes, number of days with early breaking of fasting and missed fasting days. Results: It was found that patients in SGLTi group experiences significantly fewer symptomatic (9.3 % versus 35.3 %, p=0.003) and documented (7.0 % versus 25.5 %, p=0.017) hypoglycemic episodes as compared to the SU group. However, there were no significant differences between the studied groups regarding the frequency of patients with volume depletion episodes (5.9 % versus 16.3 %, p= 0.1). Moreover, there were no significant differences between groups regarding the frequency of patients with early breaking of fasting (11.8 % versus 9.3 %, p=0.7) or missed fasting (3.9 % versus 2.3 %, p=0.66). None of the studied patients discontinued the prescribed medications. Conclusions: SGLT2i combined with metformin for diabetic patients during Ramadan fasting are effective, safe and well-tolerated with the advantage of reduced hypoglycemic events.

Get Citation

Keywords

SGLT2 inhibitors, Metformin, Sulphonylureas, Ramadan fasting, Hypoglycemia

About this article
Title

Safety and Tolerability of Sodium Glucose Co-transporter -2 Inhibitors (SGLT2i) During Ramadan Fasting

Journal

Clinical Diabetology

Issue

Ahead of print

Article type

Research paper

Published online

2021-06-17

DOI

10.5603/DK.a2021.0048

Keywords

SGLT2 inhibitors
Metformin
Sulphonylureas
Ramadan fasting
Hypoglycemia

Authors

Elsayed A. Eid
Abdelaziz M. Hussein
Hossam A. Ghazy

References (22)
  1. Ahmed MH, Husain NE, Elmadhoun WM, et al. Diabetes and Ramadan: A concise and practical update. J Family Med Prim Care. 2017; 6(1): 11–18.
  2. Abolaban H, Al-Moujahed A. Muslim patients in Ramadan: A review for primary care physicians. Avicenna J Med. 2017; 7(3): 81–87.
  3. Sadikot S, Jothydev K, Zargar AH, et al. Clinical practice points for diabetes management during RAMADAN fast. Diabetes Metab Syndr. 2017; 11 Suppl 2: S811–S819.
  4. Beshyah SA, Chowdhury TA, Ghouri N, et al. Risk of diabetic ketoacidosis during Ramadan fasting: A critical reappraisal. Diabetes Res Clin Pract. 2019; 151: 290–298.
  5. Malek R, Hannat S, Nechadi A, et al. Diabetes and Ramadan: A multicenter study in Algerian population. Diabetes Res Clin Pract. 2019; 150: 322–330.
  6. Lessan N, Ali T. Energy Metabolism and Intermittent Fasting: The Ramadan Perspective. Nutrients. 2019; 11(5).
  7. Ibrahim M, Abu Al Magd M, Annabi FA, et al. Recommendations for management of diabetes during Ramadan: update 2015. BMJ Open Diabetes Res Care. 2015; 3(1): e000108.
  8. Mbanya JC, Al-Sifri S, Abdel-Rahim A, et al. Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach. Diabetes Res Clin Pract. 2015; 109(2): 226–232.
  9. Li J, Zheng J, Wang S, et al. Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies. Front Physiol. 2017; 8: 15.
  10. El Mouhayyar C, Riachy R, Khalil AB, et al. SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review. Int J Endocrinol. 2020; 2020: 1762164.
  11. Dandona P, Chaudhuri A. Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician. Int J Clin Pract. 2017; 71(5).
  12. Shao Y, Lim GJ, Chua CL, et al. The effect of Ramadan fasting and continuing sodium-glucose co-transporter-2 (SGLT2) inhibitor use on ketonemia, blood pressure and renal function in Muslim patients with type 2 diabetes. Diabetes Res Clin Pract. 2018; 142: 85–91.
  13. Federation ID. IDF diabetes atlas eighth edition 2017.
  14. Hassanein M, Al-Arouj M, Hamdy O, et al. International Diabetes Federation (IDF), in collaboration with the Diabetes and Ramadan (DAR) International Alliance. Diabetes and Ramadan: Practical guidelines. Diabetes Res Clin Pract. 2017; 126: 303–316.
  15. Ghouri N, Hussain S, Mohammed R, et al. Diabetes, driving and fasting during Ramadan: the interplay between secular and religious law. BMJ Open Diabetes Res Care. 2018; 6(1): e000520.
  16. Wan Seman WJ, Kori N, Rajoo S, et al. Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia. Diabetes Obes Metab. 2016; 18(6): 628–632.
  17. Hassanein M, Echtay A, Hassoun A, et al. Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS). Int J Clin Pract. 2017; 71(10).
  18. Bashier A, Khalifa AA, Abdelgadir EI, et al. Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2-I) During the Month of Ramadan in Muslim Patients with Type 2 Diabetes. Oman Med J. 2018; 33(2): 104–110.
  19. Nathan KT, Ahmed-Sarwar N, Werner P. SGLT-2 Inhibitors: A Novel Mechanism in Targeting Glycemic Control in Type 2 Diabetes Mellitus. Consult Pharm. 2016; 31(5): 251–260.
  20. Weir MR, Januszewicz A, Gilbert RE, et al. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2014; 16(12): 875–882.
  21. Shubrook JH, Bokaie BB, Adkins SE. Empagliflozin in the treatment of type 2 diabetes: evidence to date. Drug Des Devel Ther. 2015; 9: 5793–5803.
  22. Tahrani AA, Barnett AH, Bailey CJ. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol. 2016; 12(10): 566–592.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl